Advertisement

A part of Watch Medier

MedWatch
  • Latest
  • Search
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Buy
MedWatch
  • Search
  • Log in
  • Buy
MedWatch

Sections

  • Latest news
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other

About MedWatch

  • Contact the editorial team
  • Our values
  • About MedWatch
  • Follow us on LinkedIn
  • Available jobs in the industry

Get access

  • Log in
  • Buy subscription
  • Subscribe to newsletters
  • Contact customer service

Apps

  • Download app for iOS
  • Download app for Android
2026 © MedWatch
A part of Watch Medier
Peter Karlstromer is the CEO of GN. | Foto: Gn / Pr
Hearing healthSubscription

GN notes positive winds in the US after tough year – plans to launch new top product in 2026

  • GN cuts debt further as dividend remains on hold

  • GN's hearing aid activities achieved organic growth of 5% in 2025

Debt-ridden GN reduced its debt by DKK 800m during 2025. | Foto: Thomas Lekfeldt
Hearing healthSubscription

GN cuts debt further as dividend remains on hold

Foto: Hollie Adams
Pharma & biotechSubscription

11 patients awarded compensation over eye disease linked to Novo products

Coloplast is expected to report its financial results for the first quarter of the staggered fiscal year 2025/26 on Friday morning. | Foto: Coloplast / PR
MedtechSubscription

Analysts expect a subdued start to the year for Coloplast: Challenges in China will continue to weigh heavily

Charl van Zyl became CEO of Lundbeck in 2023. | Foto: Magnus Møller
Pharma & biotechSubscription

Lundbeck CEO received a small pay rise in 2025

On Sunday, February 8, the Super Bowl will be held in California, where Novo Nordisk will advertise the new Wegovy tablet. | Foto: Carlos Barria
Pharma & biotechSubscription

Novo Nordisk to promote Wegovy at Super Bowl as part of intensified marketing focus

Charl van Zyl is confident despite increased price pressure and competition for the best-selling Rexulti. | Foto: Thomas Lekfeldt
Pharma & biotechSubscription

Lundbeck CEO on crucial price negotiations for blockbuster drug in the US: “We are prepared”

Jobs

Head of Sales Batch Freeze Dryer Food, GEA Process Engineering

Global Safety Lead, Global Medical Safety

Pharmacokineticist, PK/PD Modelling & Simulation

See all jobs
Britt Meelby Jensen has been CEO of Ambu since 2022. | Foto: PR/Ambu
MedtechSubscription

Ambu CEO confident in growth targets despite tough conditions from tariffs and FX

Søren Nielsen, CEO of Demant, is to cut 700 jobs as part of a major cost-cutting plan. | Photo: Kenneth Lysbjerg Koustrup
Did you read?Subscription

Major layoffs hit the Demant organization hard

As CEO of Novo Nordisk, Mike Doustdar is confident about the company's economies of scale in competition with smaller copycats.
StrategySubscription

Novo Nordisk CEO on new price pressure risk: We have economies of scale

Foto: Thomas Lekfeldt
Hearing healthSubscription

GN's hearing aid activities achieved organic growth of 5% in 2025

Lundbeck CEO Charl van Zyl has several candidates in the pipeline who are crucial to the company's future success. | Foto: Magnus Møller
Pharma & biotechSubscription

Lundbeck CEO predicts results for migraine candidate as next major catalyst

Boston Scientific competes with both Danish companies Coloplast and Ambu. | Foto: Clodagh Kilcoyne
MedtechSubscription

Boston Scientific disappoints with low forecast for 2026

The former female employee who initiated legal proceedings against Novo Nordisk ultimately had to take sick leave as a result of her experiences at the pharmaceutical company. | Foto: Finn Frandsen
Did you read?Subscription

"Belittled" and "threatened" every week: Former employee accuses Novo Nordisk in the US of sexist culture

A revision of European pharmaceutical legislation is now in place after the European Parliament and the Council reached an agreement last night on a comprehensive revision of the rules in this area. | Foto: Gonzalo Fuentes

Industry passes judgment on new drug regulation: Better than feared, but a blow to Europe's competitiveness

Read the article here
EU lands major pharmaceutical package
“A step in the wrong direction:" Industry fears consequences of new EU pharma package
The final sprint on the pharmaceutical package is underway: The battle of new medicines' protection in the EU
Mike Doustdar, CEO of Novo Nordisk. | Foto: Kenneth Lysbjerg Koustrup
Pharma & biotechSubscription

Novo Nordisk CEO refutes crisis despite negative growth forecast

Lars Rebien Sørensen, chairman of both Novo Nordisk and the Novo Nordisk Foundation, held just over half a million equities in Novo Nordisk at the end of 2025, according to a new remuneration report. | Foto: Novo Nordisk Foundation
PeopleSubscription

Lars Rebien Sørensen loses big on a terrible day for Novo on the stock market

In the fourth quarter, sales of Eli Lilly's weight loss treatment Zepbound increased by 123% compared to the same quarter last year. | Foto: Mike Blake
Pharma & biotechSubscription

Eli Lilly's Zepbound sales outperform expectations

Most read

1

Lars Rebien Sørensen loses big on a terrible day for Novo on the stock market

2

Novo Nordisk CEO takes significant pay cut

3

Novo Nordisk CEO refutes crisis despite negative growth forecast

4

"The Ozempic Pill": Novo Nordisk renames diabetes pill

5

Management resignations cost Novo Nordisk USD 35m in 2025

Novo Nordisk has just published its annual financial statement for 2025. | Foto: Tom Little
Pharma & biotechSubscription

Novo Nordisk presents financial statement for 2026: Predicts up to double-digit underlying decline

GN's headquarters are located in Ballerup. | Foto: Thomas Lekfeldt
Hearing healthSubscription

Growth forecast will be crucial in GN's annual report

Lars Fruergaard Jørgensen was dismissed as CEO of Novo Nordisk in May last year. | Foto: Jacob Ehrbahn
Pharma & biotechSubscription

Fired Novo CEO received USD 10.3m in golden handshake

Novo Nordisk CEO Mike Doustdar (left) and CFO Karsten Munk Knudsen (right) held a press conference in connection with the company's annual report. | Foto: Thomas Traasdahl
Pharma & biotechSubscription

Doustdar on poor 2026 outlook: "We don't want to disappoint ourselves or the market"

In April last year, Camilla Sylvest stepped down as commercial director at Novo Nordisk, and together with Marcus Schindler, Henrik Wulff, and Dave Moore, she received a total of DKK 118.5m in various payments. | Foto: Novo Nordisk / Pr
Pharma & biotechSubscription

Management resignations cost Novo Nordisk USD 35m in 2025

In future, semaglutide in tablet form for diabetes will be marketed under the name The Ozempic Pill instead of Rybelsus. | Foto: Novo Nordisk / Pr
Pharma & biotechSubscription

"The Ozempic Pill": Novo Nordisk renames diabetes pill

Danish Demant develops, manufactures, and sells hearing aids globally. | Foto: Demant /pr
Hearing healthSubscription

Retail now accounts for most of Demant's revenue

CEO of Novo Nordisk, Mike Doustdar. | Foto: Kenneth Lysbjerg Koustrup
Pharma & biotechSubscription

Novo Nordisk CEO takes significant pay cut

Charl van Zyl, CEO of Lundbeck. | Foto: Thomas Lekfeldt
Pharma & biotechSubscription

Lundbeck expects revenue growth of 5-8% in 2026

"The last thing we want is to disappoint our shareholders," says CFO Karsten Munk Knudsen on Tuesday evening. | Foto: Novo Nordisk / Pr
Pharma & biotechSubscription

Novo Nordisk CFO: It's a shame that we disappoint with our expectations

Ambu has just released its financial results for the first quarter of the staggered fiscal year 2025/26. | Foto: Ambu /pr
MedtechSubscription

Endoscope sales ensure growth above expectations at Ambu

Foto: Kenneth Lysbjerg Koustrup
Pharma & biotechSubscription

Novo Nordisk CEO: "Nothing going in the wrong direction"

Jobs

Senior or Principal Analytical Scientist

Senior External Reporting Manager

Programme Fellow - BioSustainability Design Novo Nordisk Foundation Fellowship Programme (BSD)

Information Security Advisor

See all jobs

Colophon

MedWatch

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • RSS feeds

Follow us on

Editor

Ulrich Quistgaard

uq@medwatch.dk

Tel.: +45 3330 8349

Read about the editorial team

Press Releases

medwatch@medwatch.dk

Debate

medwatch@medwatch.dk

We take responsibility for the content and are signed up to Pressenævnet

Editorial guidelines

  • Review of quotes by sources
  • Use of AI
  • Employee stock investments

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 70 77 71 25

Buy subscription
Company subscription

Job Advertising

job@infowatch.dk

Tel.: +45 70 77 71 25

Read more about jobs

Banner Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7125

Read more about banners

Support

Contact customer service

About MedWatch

MedWatch is a part of Watch Medier.

Read more about MedWatch

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Editor-in-chief

Rasmus Emborg

Publisher

JP/Politiken Media Group Ltd

Terms and consent

  • Cookie policy
  • Privacy policy

Copyright © MedWatch — All rights reserved

  • Hearing health

    GN notes positive winds in the US after tough year – plans to launch new top product in 2026

  • Pharma & biotech

    11 patients awarded compensation over eye disease linked to Novo products

  • Medtech

    Analysts expect a subdued start to the year for Coloplast: Challenges in China will continue to weigh heavily

  • Pharma & biotech

    Lundbeck CEO received a small pay rise in 2025

  • Hearing health

    GN cuts debt further as dividend remains on hold

  • Pharma & biotech

    Novo Nordisk to promote Wegovy at Super Bowl as part of intensified marketing focus

  • Pharma & biotech

    Lundbeck CEO on crucial price negotiations for blockbuster drug in the US: “We are prepared”

  • Medtech

    Ambu CEO confident in growth targets despite tough conditions from tariffs and FX

  • Strategy

    Novo Nordisk CEO on new price pressure risk: We have economies of scale

  • Hearing health

    GN's hearing aid activities achieved organic growth of 5% in 2025

  • More news
More news

Jobs

Head of Sales Batch Freeze Dryer Food, GEA Process Engineering

Global Safety Lead, Global Medical Safety

Pharmacokineticist, PK/PD Modelling & Simulation

Senior or Principal Analytical Scientist

Senior External Reporting Manager

Programme Fellow - BioSustainability Design Novo Nordisk Foundation Fellowship Programme (BSD)

Information Security Advisor

See all jobs

MedWatch

Novo Nordisk når ikke alle diversitetsmål for 2025
Danske Bank skruer ned for forventningerne til Lundbeck - men ser optimistisk på 2026
Lundbeck-topchef jagter stadig nye opkøb efter kamp om irsk selskab
Bristol Myers imponerer med prognosen og stiger i formarkedet

MedWatch

Laerdal Medical fortsetter KI-samarbeid med Universitetet i Stavanger
Klyv Therapeutics ansetter driftsdirektør
BMS Norge-sjefen: – Diskusjonene om kliniske studier tas i økende grad i Norden
GE Healthcare skyter inn 33 millioner kroner i Exact Therapeutics

KapitalWatch

Dansker bliver topchef i kapitalfondsejet milliardselskab
Kapitalfond købte softwarefirma for trecifret millionbeløb
Norsk advokatfirma står bag indtog: Ny M&A-trio er i gang i Danmark
Startskud til ny fond: Kapitalfonden Blue Equity køber jysk metalspecialist

AdvokatWatch

Dreiststorgaard indgår samarbejde med Dansk Håndbold
Bahr rykker ind på 2000 kvm i "et vidunder af træ"
Kromann Reumert vinder sag om prisstigninger for Tryg i Højesteret
Et af Norges største advokatfirmaer er klar til kamp i Danmark